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ABSTRACT
Tacrolimus (FK506)/mycophenolate mofetil (MMF) has been demonstrated to be an effective salvage therapy
for steroid-resistant chronic graft-versus-host disease (GVHD), but its effectiveness as prophylaxis for acute
GVHD (aGVHD) is unknown. We investigated the safety and efficacy of FK506/MMF in preventing aGVHD
and sparing the use of methotrexate and methylprednisolone in childhood and adolescent allogeneic stem cell
transplant (AlloSCT) recipients. Thirty-four childhood and adolescent patients (median age, 7 years; range,
0.5-21 years; 24 males and 10 females) undergoing 37 AlloSCTs for malignant (n  22) and nonmalignant (n 
12) disorders received FK506 (0.03 mg/kg/d by continuous intravenous infusion) and MMF (15 mg/kg per dose
orally or intravenously twice daily). Stem cell sources included 22 umbilical cord blood donors (21 unrelated
and 1 related), 6 related bone marrow donors, and 9 related peripheral blood donors. Malignant diagnoses
included 7 acute lymphoblastic leukemias, 3 acute myeloid leukemias, 1 acute promyelocytic leukemia, 2
non-Hodgkin lymphomas, 4 Hodgkin diseases, 3 chronic myeloid leukemias, and 2 neuroblastomas; nonma-
lignant diagnoses included 2 -thalassemias, 1 sickle cell disease, 4 aplastic anemias, 1 Wiskott-Aldrich
syndrome, 1 Hurler syndrome, 2 hemophagocytic lymphohistiocytoses, and 1 myelodysplastic syndrome. The
probability of developing grade >II aGVHD was 45.4%  9.7% (7 related bone marrow/related peripheral
blood; 5 umbilical cord blood), and for chronic GVHD it was 38.1% 19.7%. FK506/MMF was well tolerated.
Three patients had grade III to IV neurotoxicity (disorientation and leukoencephalopathy); 4 patients devel-
oped grade III to IV nephrotoxicity (all received concomitant nephrotoxins). Patients who achieved target
mycophenolic acid levels (1.0-3.5 g/mL) before day 30 had a significantly reduced incidence of developing
grade >II aGVHD (16.7%  15.2% versus 100%; P < .02). These results suggest that FK506/MMF is well
tolerated and may be a safe and effective methotrexate- and methylprednisolone-sparing alternative GVHD
prophylaxis regimen after AlloSCT. Further pharmacokinetic and pharmacodynamic studies are ongoing in
pediatric and adolescent AlloSCT recipients to define optimal MMF dosing.
© 2004 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Acute graft-versus-host disease (aGVHD) is a po-
entially fatal complication after allogeneic hemato-
oietic stem cell transplantation (AlloSCT) and results
n large part from alloreactive donor T cells reacting q
46gainst HLA-disparate host antigens [1]. The inci-
ence of clinically signiﬁcant aGVHD ranges from
% to 50% among HLA-matched sibling AlloSCT
ecipients and varies with the degree of histoincom-
atibility, the recipient and donor ages, the source and
uality of donor T lymphocytes, the incidence of
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FK506 and MMF for GVHD Prophylaxis after AlloSCT
Bytomegalovirus (CMV) infection, and the type of
VHD prophylaxis strategy [2]. Despite the use of
rophylactic immunosuppressive agents such as cyclo-
porine (CsA), methylprednisolone (PDN), metho-
rexate (MTX), and antithymocyte globulin, approxi-
ately 60% to 80% of patients who undergo HLA-
dentical but unrelated adult donor marrow
ransplantation without T-cell depletion and 40% to
0% of patients who receive HLA-disparate unrelated
mbilical cord blood (UCB) transplants will develop
rade II to IV aGVHD [3-5]. Furthermore, we and
thers have demonstrated that recipients of HLA-
isparate unrelated UCB transplants experience a
0% to 60% risk of developing grade II aGVHD
6-9].
Historically, CsA and MTX (with or without
DN) have been used for aGVHD prophylaxis after
atched related and unrelated allogeneic donor trans-
lantation and have been shown in randomized trials
o be superior to either drug alone in preventing
evere grade II to IV aGVHD [10,11]. Although the
fﬁcacy of these regimens (MTX and CsA with or
ithout PDN) in preventing moderate to severe
GVHD after AlloSCT ranges from 20% to 50%,
ach of these agents is also associated with signiﬁcant
rgan toxicity. CsA is associated with renal, hepatic,
nd central nervous system toxicity; unpleasant cos-
etic side effects (hirsutism and gingival hyperplasia);
nd multiple drug-drug interactions [12-15]. MTX
nhances conditioning regimen–induced mucositis;
ay cause hepatotoxicity, nephrotoxicity, and myelo-
uppression; and may secondarily delay engraftment
16]. PDNmay precipitate glucose intolerance, hyper-
ension, and osteopenia [17,18].
Tacrolimus (FK506), a heterocyclic macrolide an-
ibiotic isolated from the broth of Streptomyces tsuku-
aensis, is a new GVHD prophylaxis agent similar to
ut 50 to 200 times more potent an immunosuppres-
ant than CsA [19,20]. FK506 inhibits calcineurin,
esulting in inhibition of interleukin-2 production and
ecreased proliferation of antigen-speciﬁc T lympho-
ytes [19,20]. In 3 randomized human trials, FK506 in
ombination with standard-dose MTX was associated
ith a signiﬁcantly lower incidence of aGVHD com-
ared with CsA/MTX [21-23].
Mycophenolate mofetil (MMF), another immuno-
uppressive agent, works through its active metabolite
ycophenolic acid (MPA) on proliferating lympho-
ytes by noncompetitively inhibiting both isoforms of
nosine monophosphate dehydrogenase, the rate-lim-
ting enzyme in de novo purine synthesis [24]. MMF
ugments the efﬁcacy of standard immunosuppres-
ants without overlapping toxicities. MMF has been
emonstrated to be effective in the treatment of adults
ith aGVHD and chronic GVHD (cGVHD) [25],
esults in reduced use of PDN-based therapies, and
an be safely combined with MTX and PDN [26]. a
B&MTK506 in combination with MMF has been used ef-
ectively as salvage therapy for steroid-resistant
GVHD in adult AlloSCT recipients [27], as well as in
olid organ transplant (SOT) recipients. FK506/
MF, in comparison with CsA/MMF, seems to be
uperior in preventing allograft rejection, with im-
roved graft function at 2 years after renal cadaveric
ransplantation [28].
We postulate that this combination may be an
ffective alternative for aGVHD prophylaxis and may
dditionally allow sparing of MTX, PDN, or both.
e report preliminary results of MPA steady-state
rough concentration monitoring and its correlation
ith the development of aGVHD in this population.
ATERIALS AND METHODS
atients
Between October 2000 and April 2003, we inves-
igated the safety and efﬁcacy of FK506/MMF for
VHD prophylaxis in 37 AlloSCT patients by using
oth related and unrelated donors in 34 pediatric and
dolescent recipients (22 years old; Table 1). All
atients were enrolled on Columbia University Insti-
utional Review Board–approved protocols. All pa-
ients and/or parents signed an appropriate institu-
ional review board–approved informed consent
efore study entry. Poor-risk patients were deﬁned as
atients in malignant relapse, with progressive malig-
ant disease, and in third or greater complete malig-
ant response (CR 3) and/or those receiving a sec-
nd AlloSCT. All other patients were deﬁned as
verage risk.
LA Typing and Allogeneic Donors
HLA typing was performed by serology for
LA-A and -B and by high resolution DNA typing
or -DRB1. Matched family donors (MFD) were re-
uired to be a 6/6 or 5/6 HLA match, whereas UCB
related and unrelated) donors had to be 6/6, 5/6, or
/6 HLA matched. UCB donor units were also re-
uired to have a minimum of 1.5 107 nucleated cells
f cryopreserved UCB units per kilogram recipient
ody weight.
onditioning Regimens
Conditioning regimens were diverse; 57% of pa-
ients received myeloablative conditioning regimens,
nd 43% received ﬂudarabine-based reduced-intensity
onditioning regimens (Table 2). Eleven patients
31%) received total body irradiation.
VHD Prophylaxis
FK506 was administered either intravenously (IV)
t 0.03 mg/kg/d by continuous infusion or orally (PO)
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2t 0.12 mg/kg/d in 2 divided doses starting on day 1
r on the ﬁrst day of conditioning (protocol depen-
ent). Doses were adjusted to maintain FK506 ran-
om (IV) or trough (PO) concentrations between 5
nd 20 ng/mL (whole-blood enzyme-linked immu-
osorbent assay) [29]. Patients were converted from
V to PO FK506 at a ratio of 4:1 (PO/IV dose) when
hey were able to take medications orally. FK506 was
apered after day 60 if patients had grade II
GVHD. MMF was administered daily starting on
able 1. Patient Characteristics
Variable Data
o. patients 34 (37 AlloSCT)
edian age, y (range) 7 (0.5-21)
ex
Male 24 (70%)
Female 10 (30%)
iagnosis (n  34)
Malignant (n  22)
ALL (5 CR2, 2 CR3) 7
AML (1 CR1, 1 CR2, 1 refractory) 3
APL (CR2) 1
NHL (1 CR2, 1 PR2) 2
HD (2 CR2, 1 PD, 1 PR2) 4
CML-CP 3
Neuroblastoma (1 CR1, 1 PD) 2
Nonmalignant (n  12)
-Thalassemia 2
SCD 1
Aplastic anemia 4
WAS 1
Hurler’s syndrome 1
HLH 2
MDS 1
ransplant history
Autologous 7
Allogeneic 3
ransplant source (allogeneic)
Cord blood 22 (57%)
Marrow 6 (18%)
PBSC 9 (25%)
reparative regimen
Reduced intensity 16 (43%)
Myeloablative 21 (57%)
LA disparity
None (6/6) 16
Class I (5/6) 6
Class II (5/6) 1
Double class I (4/6) 9
Class I and II (4/6) 3
Double class II (4/6) 2
LL indicates acute lymphoblastic leukemia; AML, acute myelog-
enous leukemia; APL, acute promyelocytic leukemia; NHL,
non-Hodgkin lymphoma; HD, Hodgkin disease; CML-CP,
chronic myelogenous leukemia in chronic phase; SCD, sickle
cell disease; WAS, Wiscott-Aldrich syndrome; HLH, hemo-
phagocytic lymphohistiocytosis; MDS, myelodysplastic syn-
drome; PBSC, peripheral blood stem cell; PD, progressive dis-
ease; CR, complete response; PR, partial response.ay1 at a dose of 15 mg/kg per dose IV or PO twice
48aily. Beginning in January 2002, MMF doses were
djusted to maintain MPA trough concentrations
ithin a reference range of 1 to 3.5 g/mL. Patients
ere initiated on IV MMF and were converted to a
O formulation when this was clinically appropriate
r when the IV formulation was not available. MPA/
PA glucuronide (MPAG) trough concentrations
ere obtained after 3 consecutive days of dosing at
ach MMF dose level and upon switching from an IV
o PO formulation. MPA/MPAG trough concentra-
ions were monitored every 2 weeks in patients who
chieved target levels. MMF was discontinued or ta-
ered after day 28 (per each individual protocol) if
atients had grade II aGVHD.
GVHD was graded according to the Seattle con-
ensus criteria [30]. The “rule of 9” or a burn chart
as used to estimate the extent of skin rash. Patients
ere staged and graded once a week for the occur-
ence of aGVHD. Once a clinical diagnosis of
GVHD or cGVHD was determined, histologic con-
rmation was obtained if possible.
K506/MPA Trough Concentrations
FK506 whole-blood concentrations were mea-
ured with the IMx Tacrolimus II assay (Abbott Lab-
ratories, Abbott Park, IL) [29] based on the macro-
article enzyme immunoassay technique. Blood
amples for the FK506 assay were drawn through
ndwelling catheters not used for infusion of FK506.
able 2. Conditioning Regimens
Regimen n
yeloablative (n  21)
TBI/Cy 3
TBI/Cy/Etopophos 2
TBI/Cy/thiotepa/ATG 1
TBI/Mel 3
TBI/Mel/CAMPATH 1
TBI/Mel/ATG 1
Cy/ATGAM 1
Bu/Cy 2
Bu/Cy/CAMPATH 2
Bu/Mel/ATG 2
Bu/Cy/ATG/VP-16 1
Flu/Cy/ATG 2
onmyeloablative (n  16)
Flu/Bu/ATG 7
Flu/Cy/ATG 5
Flu/Bu/CAMPATH 2
Flu/Cy/Etopophos/ATG 1
Flu/Bu 1
BI indicates total body irradiation (1200 cGy); Bu, busulfan
(6.4-16 mg/kg); Flu, ﬂudarabine (150-180 mg/m2); Cy, cyclo-
phosphamide (120 mg/kg); Mel, melphalan (135 mg/m2); ATG,
rabbit antithymocyte globulin (4.5-8 mg/kg); ATGAM, horse
antithymocyte globulin (90 mg/kg); CAMPATH, alemtuzumab
(54 mg/m2); Etopophos, etoposide phosphate (40 mg/kg); VP-
16, etoposide (30 mg/kg).
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FK506 and MMF for GVHD Prophylaxis after AlloSCT
BSerum levels of MPA and MPAG were deter-
ined by using reverse-phase high-performance liq-
id chromatography (Shimadzu, Kyoto, Japan) [31]. A
otal of 2 to 3 mL of peripheral blood was drawn into
red-topped (plain) tube, and plasma was separated
nd shipped to Mayo Clinical Laboratories (Roches-
er, MN) for analysis.
upportive Care
All patients were hospitalized in protective isola-
ion, deﬁned as private/single rooms with a high-
fﬁciency particulate air ﬁltration system and reverse
solation with mask and strict hand washing. Broad-
pectrum antibiotics were used to treat initial episodes
f febrile neutropenia. All patients received anti-infec-
ive prophylaxis against Pneumocystis carinii pneumo-
ia, fungal infections, herpes simplex virus, and CMV
seropositive recipients and/or donors only). Tri-
ethoprim/sulfamethoxazole for Pneumocystis carinii
neumonia prophylaxis was given daily during the
reparative regimen until day 2 and was resumed
fter transplantation at 5 mg/kg/d PO divided twice
aily 3 times a week upon myeloid engraftment (ab-
olute neutrophil count [ANC] 500/mm3 for 2 con-
ecutive days). Patients who did not engraft by day
42 were given pentamidine 4 mg/kg IV every 2
eeks. All but 2 patients received fungal prophylaxis
ith liposomal amphotericin B at 3 mg/kg/d IV over
hours starting on day 0 until day 100, as we have
reviously described [32]. Acyclovir 250 mg/m2 per
ose IV was administered every 8 hours for herpes
implex virus prophylaxis to all patients until myeloid
ngraftment and resolution of mucositis (grade II).
atients who were CMV seropositive or who received
llogeneic stem cells from a CMV-seropositive donor
ere given a prophylactic alternate-day regimen of IV
oscarnet (90 mg/kg per dose every 48 hours) alter-
ating with IV ganciclovir (5 mg/kg per dose every 48
ours) starting after myeloid engraftment until day
100 if no GVHD was evident, as we have previously
escribed [33].
All patients received hematopoietic growth factors
tarting on day 0 with sargramostim (granulocyte-
acrophage colony-stimulating factor) at 250 g/
2/d IV over 2 hours within 3 hours of stem cell
nfusion until the white blood cell count was 300/
m3 for 2 consecutive days. Patients were then
witched to ﬁlgrastim (granulocyte colony-stimulating
actor; G-CSF) at 10 g/kg/d IV over 15 to 30 min-
tes. This was tapered by 50% when ANC reached
2500/mm3 for 2 days.
Irradiated, leukodepleted packed red blood cell
ransfusions of 10 to 15 mL/kg were given to maintain
emoglobin8.0 g/dL. Patients received transfusions
f 1 random unit of irradiated leukodepleted platelets o
B&MTer 10 kg body weight to maintain platelet counts
20000/mm3. All blood products were leukodepleted
y using a 170- to 250-m ﬁlter and irradiated with
5 Gy. All CMV-seronegative patients with CMV-
egative donors received leukocyte-reduced or CMV-
eronegative blood products to prevent transfusion-
ssociated CMV infection. Patients were also followed
p clinically for the development of veno-occlusive
isease, which was graded for severity by using the
riteria of Bearman et al. [34].
tatistical Analysis
Results are presented as medians with speciﬁed
anges of data sets. Probabilities of survival and inci-
ences of aGVHD or cGVHD were calculated with
he Kaplan-Meier method performed with the Prism
tatistical program (Graph Pad, San Diego, CA).
ESULTS
atients and Donors
FromOctober 2000 to April 2003, 34 children and
dolescents with malignant and nonmalignant disease
eceived 37 AlloSCT MFD or UCB transplants at the
hildren’s Hospital of New York-Presbyterian. Pa-
ient characteristics are summarized in Table 1. The
edian age was 7 years (range, 0.5-21 years). The sex
istribution was 24 males and 10 females. The disease
istribution was as follows: 7 patients with acute lym-
hoblastic leukemia (5 in CR2 and 2 in CR3), 3 with
cute myeloid leukemia (1 in CR1, 1 in CR2, and 1
efractory), 3 with chronic myeloid leukemia (CML;
hronic phase), 4 with Hodgkin disease (2 in CR2, 1 in
econd partial response, and 1 with progressive dis-
ase), 2 with non-Hodgkin lymphoma (1 in CR2 and
in second partial response), 2 with neuroblastoma
1 in CR1 with aplasia and 1 with progressive disease),
with aplastic anemia (severe), 2 with hemophagocytic
ymphohistiocytosis (HLH), and 2 with -thalassemia.
ne patient each had sickle cell disease, Wiskott-
ldrich syndrome, Hurler syndrome, acute promyelo-
ytic leukemia (CR2), and myelodysplastic syndrome
MDS) without malignant transformation.
Three patients underwent a second AlloSCT be-
ause of graft failure. Two (1 each with B thalassemia
nd Hurler’s syndrome) had undergone a prior re-
uced-intensity transplantation and underwent re-
ransplantation on days 124 and 62. One patient
ith HLH had received a prior fully ablative trans-
lant and underwent retransplantation on day 183.
one of these patients was evaluable for aGVHD or
GVHD before receiving their second transplant.
Patients received AlloSCTs from either MFD
n  15) or UCB (n  22) (Table 3). Eight 6/6 and
ne 5/6 HLA-matched MFD received G-CSF–mobi-
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2ized peripheral blood stem cells (PBSC); ﬁve 6/6-
atched and one 5/6-matched MFD received
-CSF–mobilized bone marrow. There were three
/6, ﬁve 5/6, and fourteen 4/6 HLA-matched UCB
ecipients. Mismatches for the UCB units were as
ollows: 6 class I, 1 class II, 3 class I and II, 2 double
lass II, and 9 double class I.
For all patients, the median nucleated cell dose
as 7.99 107/kg (range, 1.12-201 107/kg), and the
edian CD34 cell dose was 5.15  105/kg (range,
.43-97.7  105/kg). For all MFD recipients, the
7
able 3. Patient Demographics, Allogeneic Stem Cell Source, HLA Ma
Patient
No.
Age
(y) Sex
Disease
Status HLA/Donor M
99-068 2 M ALL CR2 4/6 UCB C
99-072 16 F CML-CP 6/6 PBSC 0
99-073 14 M AML PD* 5/6 UCB C
99-075 12 M AA 6/6 BM 0
99-077 6 F ALL CR2 6/6 PBSC 0
99-079 18 M AML CR2 4/6 UCB C
99-080 10 F NHL CR2 4/6 UCB C
99-081 8 F ALL CR2 4/6 UCB C
99-083 20 M HD PD* 4/6 UCB C
99-085 5 M NBL PD* 4/6 UCB C
99-086 3 M Sickle cell 6/6 BM 0
99-088 2 M WAS 5/6 UCB C
99-091 11 M ALL CR3* 5/6 UCB C
01-001 17 F HD CR2 4/6 UCB C
01-002 21 M HD CR2 6/6 PBSC 0
01-003 18 F HD PR2* 4/6 UCB C
01-004 11 M NHL PR2 4/6 UCB C
03-001 0.5 F B-Thal 5/6 UCB C
03-002 1.5 M B-Thal 6/6 BM 0
99-095 0.75 M HLH 6/6 UCB 0
99-093 3 M ALL CR2 6/6 PBSC 0
99-098 16 M APL CR2 6/6 PBSC 0
99-101 14 F ALL CR2 6/6 PBSC 0
05-001 14 M CML-CP 4/6 UCB C
05-002 16 M CML-CP 6/6 PBSC 0
99-099 1.5 M AML 4/6 UCB C
99-100 1.5 M Hurler’s 6/6 BM 0
03-001 1 F B-Thal* 4/6 UCB† C
99-095 1.5 M HLH* 6/6 UCB† 0
99-100 1.5 M Hurler’s* 6/6 PBSC† 0
99-106 4 F NBL CR1 6/6 UCB 0
99-102 6 M ALL CR3* 5/6 PBSC C
09-001 7 F AA 5/6 BM C
09-003 4 M AA 5/6 UCB C
09-004 12 M AA 6/6 BM 0
09-005 14 M HLH 4/6 UCB C
04-001 1 M MDS 4/6 UCB C
LL indicates acute lymphoblastic leukemia; CML, chronic myelo
non-Hodgkin lymphoma; HD, Hodgkin disease; NBL, neurobl
hemophagocytic lymphohistiocytosis; CR, complete response;
umbilical cord blood; PBSC, peripheral blood stem cells; BM,
irradiation; Mel, melphalan; Flu, ﬂudarabine; Cy, cyclophospham
globulin; Etop, etoposide phosphate; Bu, busulfan; Alem, alemt
APL, acute promyelocytic leukemia.
Poor-risk patients.
Second AlloSCT.edian nucleated cell dose was 64.3  10 /kg (range, w
50.9-189.7  107/kg), and the median CD34 cell dose
as 51.1  105/kg (range, 0.58-97.7  105/kg). The
edian total neutrophil count and CD34 counts for
atched family bone marrow recipients were
05.55  107 (range, 22.5-189.7  107) and 65.4 
05 (range, 23.8-78.6  105), respectively, and for
atched family PBSC recipients they were 63.9 107
range, 4.9-164.8  107) and 50.6  105 (range, 5.8-
7.7  105), respectively. For recipients of UCB, the
edian nucleated cell dose was 5.9  107/kg (range,
.12-201  107/kg), and the median CD34 cell dose
5 5
ll Dose, and Preparative Regimen
ch
TNC
(kg  107)
CD34
(kg  105)
Preparative Regimen
(RI versus M)
 2 6.5 3.76 TBI/Mel (M)
30.9 46.6 Flu/Cy/ATG (RI)
1.12 0.6 TBI/Mel (M)
51.4 78.6 Cy/ATGAM (M)
5.1 7.6 TBI/Cy/Etop (M)
1.42 0.43 TBI/Cy (M)
3.67 3.1 TBI/Cy (M)
 2 3.81 2.8 TBI/Cy (M)
2 1.64 0.89 Flu/Cy/ATG (RI)
2 6.8 1.65 Flu/Bu/ATG (RI)
22.5 51.3 Bu/Cy (M)
6.78 2.14 Flu/Cy/ATG (RI)
2.13 1.28 TBI/Mel/ATG (M)
2 2.85 1 Flu/Bu/ATG (RI)
47.0 53.3 Flu/Bu (RI)
2 4.9 4.4 Flu/Bu/ATG (RI)
2 3.77 1.96 Flu/Bu/ATG (RI)
9.5 5.32 Flu/Bu/ATG (RI)
154.8 63.4 Fu/Bu/Alem (RI)
10.4 2.26 Bu/Cy/ATG/VP-16 (M)
4.9 5.8 TBI/Mel (M)
63.9 51.1 Bu/Cy (M)
67.4 50.6 TBI/Cy/Etop (M)
2 1.61 0.77 Flu/Bu/ATG (RI)
78.2 46.1 Flu/Bu/Alem (RI)
2 11 8.48 Bu/Mel/ATG (M)
67.3 23.8 Flu/Cy/ATG (RI)
2 16.9 5.15 Bu/Cy/Alem (M)
6.3 4.1 TBI/Mel/Alem (M)
164.8 97.7 Bu/Cy/Alem (M)
7.96 2.96 Bu/Mel/ATG (M)
64.3 50.8 TBI/Thio/Cy/ATG (M)
143.8 50.4 Flu/Cy/ATG (M)
5.5 3.6 Flu/Cy/ATG (M)
189.7 64.1 Flu/Cy/ATG (RI)
201 36 Flu/Cy/Etop/ATG (RI)
2 7.99 2.88 Flu/Bu/ATG (RI)
emia; AML, acute myeloid leukemia; AA, aplastic anemia; NHL,
; WAS, Wiskott-Aldrich syndrome; B-Thal, -thalassemia; HLH,
rtial response; PD, progressive disease; CP, chronic phase; UCB,
arrow; RI, reduced intensity; M, myeloablative; TBI, total body
TG, rabbit antithymocyte globulin; ATGAM, horse antithymocyte
; VP-16, etoposide; Thio, thiotepa; TNC, total neutrophil count;tch, Ce
ismat
lass II
lass I
lass I/II
lass I/II
lass II
lass I 
lass I 
lass I
lass I
lass I 
lass I 
lass I 
lass I
lass I 
lass I 
lass I 
lass I
lass II
lass I
lass I/II
lass I 
id leuk
astoma
PR, pa
bone m
ide; A
uzumabas 2.84  10 /kg (range, 0.43-36  10 /kg).
I
C
a
o
I
p
t
9
l
U
T
2
T
h
p
m
o
r
(
1
M
s
p
i
d
a
b
M
a
d
h
M
S
m
p
t
m
1
p
r
a
c
t
c
g
t
(
d
M
t

n
d
w
s
b
t
b
c
a
a
o
a
w
w
a
1
H
r
d
m
f
S
(
d
p
a
6

r
F
I
o
(
G
p
o
FK506 and MMF for GVHD Prophylaxis after AlloSCT
Bncidence and Severity of GVHD (Acute and
hronic)
Twenty-seven patients were evaluable for
GVHD and 21 for cGVHD. Twelve patients devel-
ped grade II aGVHD. Eight of these were grade
II or IV. During the study period, the Kaplan-Meier
robability of developing grade II to IV and grade III
o IV aGVHD was 45.4% 	 9.7% and 33.8% 	
.9%, respectively (Figure 1). Four patients developed
imited cGVHD (2 PBSC, 1 bone marrow, and 1
CB). None developed extensive cGVHD (Table 4).
he probability of developing limited cGVHD for all
1 evaluable patients was 38.1% 	 19.7% (Figure 1).
he probability of developing gradeII aGVHD was
igher with related PBSC (62.5% 	 17.1%) com-
ared with UCB (37.1% 	 13.2%) or related bone
arrow (40.0% 	 21.9%; Figure 2). The probability
f developing grade III to IV aGVHDwas higher with
elated PBSC (50.0% 	 17.7%) compared with UCB
22.6% 	 11.5%) or related bone marrow (20.0% 	
7.9% (Figure 3).
PA Trough Concentrations and aGVHD
During the second half of the study, we assessed
teady-state MPA/MPAG trough concentrations in 14
atients. Of these, 8 patients (57%) received reduced-
ntensity conditioning regimens. Two of 14 patients
eveloped primary graft failures and were not evalu-
ble for GVHD. All patients had MPA and MPAG
elow the target range (MPA 0.6 g/mL and
PAG 17 g/mL) during the initial dosing period
igure 1. The probability of patients developing grade II to IV or
II to IV aGVHD and cGVHD. The probability of patients devel-
ping grade II to IV (——) or III to IV aGVHD (----) or cGVHD
-  -  -) was determined by the method of Kaplan and Meier.
VHD was graded according to the Seattle consensus criteria, and
atients were staged and graded prospectively once a week for the
ccurrence of aGVHD.t 15 mg/kg IV or PO every 12 hours (Table 5). MMF (
B&MToses were increased to 15 mg/kg IV every 6 to 8
ours in 5 patients without signiﬁcant changes in
PA or MPAG trough concentrations (Figure 4A).
ix patients subsequently received MMF at 600
g/m2 PO or IV every 6 hours. Two (33%) of 6
atients at 600 mg/m2 every 6 hours achieved the
argeted MPA concentrations (mean, 1.15 	 0.15 g/
L). MMF doses were further increased to 900 to
200 mg/m2 IV or PO every 6 hours in the next 8
atients, 5 of whom achieved MPA within the target
ange (Figure 4A). Six of 7 patients with grade II
GVHD did not achieve targeted MPA trough con-
entrations before GVHD onset (Table 5). Five of
hese 6 patients received full-intensity conditioning.
Five of 14 patients achieved target MPA trough
oncentrations within 30 days after AlloSCT and had
rade I aGVHD (Figure 4B). Four of these 5 pa-
ients received reduced-intensity conditioning. Five
62.5%) of the 8 patients who received related PBSCs
eveloped grade II to IV aGVHD. We had assessed
PA trough concentrations in only 4 of these 8 pa-
ients (1 achieved the target MPA trough before day
30 and developed grade I skin aGVHD; 3 patients
ever achieved target MPA trough concentrations and
eveloped grade III-IV aGVHD). Ten of 12 patients
ere initiated on IV MMF on day 1 and were
ubsequently switched to the PO formulation when it
ecame clinically appropriate. We were unable to de-
ect any differences in MPA trough concentrations
etween PO and IV MMF formulations, possibly be-
ause of a small sample size, wide variability in dosing,
nd good oral bioavailability of the drug.
Failure to achieve target MPA levels before day 30
fter AlloSCT was associated with a higher probability
f developing moderate to severe aGVHD. The prob-
bility of developing grade II aGVHD in patients
ho did not achieve an MPA trough level 1 g/mL
as signiﬁcantly higher compared with recipients who
chieved a level 1 g/mL (100% versus 16.7% 	
5.2%; P  .02; Figure 4B).
ematologic Recovery
Twenty-six patients were evaluable for myeloid
ecovery (ANC 500/mm3 for 2 days). Two patients
ied too early to be evaluable for myeloid engraft-
ent. Eight patients in our study experienced graft
ailure and had autologous myeloid reconstitution.
even of these patients developed primary graft failure
1 each with -thalassemia, MDS, and Hurler syn-
rome and 2 each with HLH and CML [in chronic
hase]). One patient with -thalassemia had second-
ry graft failure with a maximum donor chimerism of
5% on day 30, which decreased to 0% by day
100. Of the 8 patients with graft failure, 7 received
educed-intensity conditioning, with only 1 patient
HLH) receiving full ablation. Seven of these patients
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2eceived unrelated cord blood as the source of donor
tem cells. The median time to ANC recovery was 16
ays (range, 3-79 days). The median time to recovery
or evaluable MFD was 13.5 days (range, 11-17 days),
nd that for UCB was 23 days (range, 3-79 days;
igure 5A). Myeloid engraftment occurred earlier
ith MFD AlloSCT compared with UCB donors.
eventeen patients were evaluable for platelet recov-
ry (platelet count 20000/mm3 untransfused for 7
ays), 7 had primary graft failures, 7 died too early to
e evaluable, and 4 did not achieve platelet recovery.
he median time to platelet recovery was 19 days
able 4. Incidence and Severity of Acute and Chronic GVHD and Sur
Patient
No.
Age
(y) Sex
Disease
Status
Donor
Source
HL
Mat
99-068 2 M ALL CR2 UCB 4/
99-072 16 F CML-CP PBSC 6/
99-073 14 M AML Rel* UCB 5/
99-075 12 M AA BM 6/
99-077 6 F ALL CR2 PBSC 6/
99-079 18 M AML CR2 UCB 4/
99-080 10 F NHL CR2 UCB 4/
99-081 8 F ALL CR2 UCB 4/
99-083 20 M HD PD* UCB 4/
99-085 5 M NBL PD* UCB 4/
99-086 3 M Sickle cell BM 6/
99-088 2 M WAS UCB 5/
99-091 11 M ALL CR3* UCB 5/
01-001 17 F HD CR2 UCB 4/
01-002 21 M HD CR2 PBSC 6/
01-003 18 F HD PR2* UCB 4/
01-004 9 M NHL PR2 UCB 4/
03-001 0.5 F B-Thal UCB 5/
03-002 1.5 M B-Thal BM 6/
99-095 0.75 M HLH UCB 6/
99-093 3 M ALL CR2 PBSC 6/
99-098 16 M APL CR2 PBSC 6/
99-101 14 F ALL CR2 PBSC 6/
05-001 14 M CML CP UCB 4/
05-002 16 M CML-CP PBSC 6/
99-099 1.5 M AML UCB 4/
99-100 1.5 M Hurler’s BM 6/
03-001 1 F B-Thal* UCB† 4/
99-095 1.5 M HLH* UCB† 6/
99-100 1.5 M Hurler’s* PBSC† 6/
99-106 4 F NBL CR1 UCB 6/
99-102 6 M ALL CR3* PBSC 5/
09-001 7 F AA BM 5/
09-003 4 M AA UCB 5/
09-004 12 M AA BM 6/
09-005 14 M HLH UCB 4/
04-001 1 M MDS UCB 4/
LL indicates acute lymphoblastic leukemia; CML, chronic myeloge
non-Hodgkin lymphoma; HD, Hodgkin disease; NBL, neurobl
hemophagocytic lymphohistiocytosis; MDS, myelodysplastic sy
disease; CP, chronic phase; UCB, umbilical cord blood; PBSC, p
applicable; NE, not evaluable; Rel, relapsed; APL, acute promy
Poor-risk patients.
Second AlloSCT.range, 1-206 days). Similarly, platelet engraftment e
52ccurred earlier with evaluable MFD donors (12.5
ays; range, 8-26 days) compared with UCB donors
28 days; range, 6-206 days; Figure 5B).
oxicity and Complications
Opportunistic Infections. There were 16 docu-
ented opportunistic infections in 37 AlloSCT recip-
ents. One patient had central venous catheter fungal
nfections with Candida parapsilosis that were effec-
ively treated by increased doses of liposomal ampho-
ericin B and removal of the infected indwelling cath-
Maximum
Grade of
aGVHD
Day of
Onset
Maximum
Grade of
cGVHD
Day of
Onset
Survival
(d)
0 N/A 0 N/A D 337
NE N/A NE N/A A 984
NE N/A NE N/A D 17
0 N/A Limited 258 A 989
II 27 0 N/A D 469
0 N/A NE N/A D 28
II 13 0 N/A A 924
IV 14 NE N/A D 41
0 N/A NE N/A D 78
III 40 NE N/A D 40
0 N/A 0 N/A A 766
III 53 0 N/A D 223
0 N/A 0 N/A D 212
0 N/A 0 N/A A 831
0 N/A Limited 186 A 832
0 N/A Limited 521 D 630
0 N/A 0 N/A A 516
NE N/A NE N/A A 656
III 34 0 N/A A 500
0 N/A 0 N/A D 217
III 10 Limited 311 A 689
0 N/A 0 N/A A 599
III 23 0 N/A D 186
NE N/A NE N/A A 575
I 28 0 N/A A 429
NE N/A NE N/A D 417
NE N/A NE N/A D 210
II 23 0 N/A A 532
NE N/A N/E N/A D 34
III 30 0 N/A D 148
I 24 0 N/A D 110
IV 11 NE N/A D 44
II 31 NE N/A D 59
0 N/A 0 N/A A 365
0 N/A 0 N/A A 328
NE N/A NE N/A A 283
NE N/A NE N/A A 218
ukemia; AML, acute myeloid leukemia; AA, aplastic anemia; NHL,
; WAS, Wiskott-Aldrich syndrome; B-Thal, -thalassemia; HLH,
e; CR, complete response; PR, partial response; PD, progressive
ral blood stem cells; BM, bone marrow; A, alive; D, dead; N/A, not
c leukemia.vival
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FK506 and MMF for GVHD Prophylaxis after AlloSCT
Bspergillosis had a reactivation of Aspergillus infection
fter AlloSCT and subsequently died from cGVHD.
wo other patients developed pulmonary aspergillosis
fter UCB AlloSCT: 1 on day 42 before myeloid
ngraftment and 1 on day 209. Both of these pa-
ients died: 1 from disseminated CMV and 1 from
rogressive disease. One other patient also developed
isseminated CMV and died of multiorgan failure on
ay 41. During the study, there was a 6-month
eriod of increased nosocomial infections with adeno-
irus in our institution. Six patients with disseminated
denovirus disease died, mostly secondary to multior-
an failure and/or disease, whereas 2 with localized
isease were alive and free of adenoviral infection at
he last follow-up.
Noninfectious Toxicity. Sixteen patients (43%) de-
eloped grade II to III mucositis. The incidence of
ucositis was higher after fully ablative conditioning
egimens (14 [67%] of 21 patients) versus reduced-
ntensity regimens (2 [12.5%] of 16 patients). No
atient developed moderate to severe veno-occlusive
isease, but 1 patient developed mild to moderate
eno-occlusive disease. Three patients developed neu-
otoxicity secondary to FK506 (1 patient recovered
ully, 1 recovered partially, and 1 died of leukoenceph-
lopathy). Eighteen (48.6%) of 37, 12 (32.4%) of 37,
nd 4 (10.8%) of 37 AlloSCT recipients developed
rade III to IV hyperkalemia, hypokalemia, and hy-
omagnesemia, respectively. Four patients developed
rade III to IV nephrotoxicity (10.8%) while also
eceiving other nephrotoxic drugs, including liposo-
al amphotericin B, foscarnet, ganciclovir, vancomy-
in, and aminoglycosides. One patient developed
rade III pulmonary toxicity (radiation pneumonitis)
igure 2. Probability of developing grade II or higher or grade III
o IV aGVHD. The probability of developing grade II or higher or
rade III to IV aGVHD in patients who received AlloSCT from
eripheral blood (PBSC; ——), bone marrow (BM; -  -  -), or
nrelated cord blood units (UCB; ----) was determined by the
ethod of Kaplan and Meier.hat required prolonged steroid therapy. M
B&MTurvival
Sixteen patients have died with a median fol-
ow-up of 333 days (range, 17-989 days) for survival
nd cGVHD. Immediate causes of death were as fol-
ows: 1 pulmonary hemorrhage, 1 idiopathic pneumo-
ic syndrome, 4 multiorgan failures, 6 progressive
iseases, 1 disseminated adenovirus, 1 FK506 neuro-
oxicity, 1 GVHD, and 1 systemic CMV. The prob-
bility of 1-year overall survival (OS) for all patients
as 47.1% (95% conﬁdence interval, 27.6%-66.6%).
he probability of 1-year OS for average-risk patients
as 55.7% 	 12.0% (95% conﬁdence interval,
2.3%-79.1%), and for poor-risk patients it was
7.5% 	 17.1% (95% conﬁdence interval, 4.0%-
1.0%; Figure 6).
Two of the 3 patients who underwent a second
lloSCT died. One died on posttransplantation day
148 without evidence of cGVHD, and the second
ied on day 34, before hematologic recovery. The
hird patient is alive and free of cGVHD at 532 days
17 months) after transplantation. Only 2 of these 3
atients with follow-up 100 days after retransplan-
ation were considered evaluable for cGVHD.
ISCUSSION
The results of this study demonstrate that the
ombination of FK506 and MMF seems to be a safe
nd effective regimen for GVHD prevention after
yeloablative and reduced-intensity AlloSCT in
hildhood and adolescent recipients. Potential advan-
ages of this regimen are that it spares the prophylactic
se of corticosteroids (which have been associated
ith glucose intolerance, hypertension, and osteope-
ia) and MTX (which may enhance conditioning reg-
igure 3. Probability of developing grade III to IV or higher
GVHD. The probability of developing grade III to IV or higher
GVHD in patients who received AlloSCT from peripheral blood
PBSC; ——), bone marrow (BM; -  -  -), or unrelated cord blood
nits (UCB; ----) was determined by the method of Kaplan and
eier.
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2men-induced mucositis, liver and renal toxicity, and
yelosuppression and may secondarily delay engraft-
ent) [16]. The safety proﬁle of MMF is superior to
hat of corticosteroids or MTX: mild myelosuppres-
ion and gastrointestinal toxicity (diarrhea) are the
ost commonly reported adverse events.
There was a 9% incidence of grade III to IV
eurotoxicity associated with FK506 use in this study.
K506 can cause mild to severe neurotoxicity that can
e concentration independent, whereas dose reduc-
ion or drug discontinuation often leads to regression
f symptoms. Mild neurotoxicity associated with the
se of FK506 (headache, tremors, paresthesia, and
nsomnia) has been reported to occur in 19% to 64%
f SOT recipients [35,36]. Moderate to severe neuro-
able 5. Patient Demographics, MMF Doses, MPA Concentrations, an
Patient
No.
Age
(y) Sex
Disease
Status
Donor
Source Mismatch Co
03-001 1 F B-thal UCB Class I Ablat
03-002 1.5 M B-thal BM 0 Ablat
99-100 1.5 M Hurler’s PBSC 0 Ablat
99-088 2.5 M WAS UCB Class I Redu
99-102 6 M ALL CR3 PBSC Class I Ablat
01-004 9 M NHL PR UCB 2 class I Redu
99-101 14 F ALL CR2 PBSC 0 Ablat
05-002 16 M CML PBSC 0 Redu
99-106 4 F NBL CR1 UCB 0 Redu
09-001 7 F AA BM Class II Ablat
09-003 4 M Severe AA UCB Class I Ablat
09-004 12 M Severe AA BM 0 Redu
CB indicates umbilical cord blood; BM, bone marrow; PBSC, p
syndrome; ALL, acute lymphoblastic leukemia; CR, complete
chronic myelogenous leukemia; NBL, neuroblastoma; AA, apla
Two patients who had their MPA trough concentrations monitore
therefore were not evaluable for GVHD and were excluded fro
igure 4. A, Relationship between MMF dose and steady-state MP
GVHD with regard to MPA trough levels. The probability of deve
rough level 1 g/mL (——) compared with those recipients who
aplan and Meier.
54oxicity (seizures, confusion, hallucinations, leukoen-
ephalopathy, and cortical blindness) can occur in up
o 32% of patients [37,38].
Preliminary data from Pavletic et al. [39] suggest
hat FK506/MMF possesses a superior safety proﬁle,
s associated with a lower incidence of aGVHD, and is
ssociated with earlier myeloid/platelet engraftment
ompared with a CsA/low-dose MTX regimen. In
heir study, 23 adults with hematologic malignancies
nderwent fully ablative matched related donor Al-
oSCT and received FK506 at 0.03 mg/kg/d IV con-
inuously until day 60 plus MMF 15 mg/kg IV or
O every 12 hours until day 28 for GVHD prophy-
axis. Outcomes were compared with those of 23
atched historical controls who received CsA/MTX
GVHD*
ing
First MMF
Dose Frequency Route
Target
MPA
Reached
Acute
GVHD
(Grade)
15 mg/kg q12h IV No II
15 mg/kg q12h IV Yes III
15 mg/kg q8h IV No III
ensity 15 mg/kg q12h PO No III
15 mg/kg q8h IV No IV
ensity 15 mg/kg q12h PO Yes No
15 mg/kg q12h IV No III
ensity 600 mg/m2 q6h IV Yes I
ensity 900 mg/m2 q6h IV Yes I
900 mg/m2 q6h IV No II
900 mg/m2 q6h IV Yes No
ensity 900 mg/m2 q6h IV Yes No
al blood stem cells; B-thal, -thalassemia; WAS, Wiskott-Aldrich
se; NHL, non-Hodgkin lymphoma; PR, partial response; CML,
mia; IV, intravenous; PO, oral.
oped primary graft failure after reduced-intensity conditioning and
table.
gh concentrations. B, Probability of developing grade II or higher
rade II or higher aGVHD in patients who did not achieve an MPA
ed a level 1 g/mL (— - - —) was determined by the method ofd Acute
ndition
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ive
ive
ced int
ive
ced int
ive
ced int
ced int
ive
ive
ced int
eripher
respon
stic ane
d devel
m theA trou
loping g
achiev
G
m
a
d
.
T
m
d
r
6
2
r
p
c
4
p
A
u
k
p
t
p
h
o
t
a
i
m
o
a
b
i
t
h
s
(
g
s
p
t
s
d
t
a
pF
f
(
—
t
a

m
(
w
F
o
K
u
t
FK506 and MMF for GVHD Prophylaxis after AlloSCT
BVHD prophylaxis at the same institution. The cu-
ulative incidence of grades II to IV and III to IV
GVHD in FK506/MMF versus CsA/MTX at 100
ays after transplantation was 15% versus 62% (P 
0003) and 6% versus 25% (P  .025), respectively.
he median time to neutrophil and platelet engraft-
ent in study patients versus controls was 10 versus 15
ays (P  .001) and 13 versus 19 days (P  .11),
espectively. There was no difference in OS or
-month cumulative incidence of relapse between the
GVHD prophylaxis groups.
igure 5. A, Probability of myeloid engraftment (ANC 500/mm3
or 2 days) determined by the Kaplan-Meier method in all patients
----) and patients who received either umbilical cord blood (UCB;
—) or matched family donor (MFD; ——) allogeneic stem cell
ransplants. Patients who did not engraft were excluded from data
nalysis. B, Probability of platelet (Plt) engraftment (Plt count
20000/mm3 for 7 days) was determined by the Kaplan-Meier
ethod in all patients (---) and in patients who received either UCB
——) or MFD (——) allogeneic stem cell transplants. Patients
ho did not engraft were excluded from the data analysis.The use of MMF-containing immunosuppressive (
B&MTegimens is common in SCT; however, there is a
aucity of data on the pharmacokinetics and pharma-
odynamics of MMF in this patient population [40-
2]. There seem to be signiﬁcant differences in the
harmacokinetics and pharmacodynamics of MMF in
lloSCT recipients compared with healthy adult vol-
nteers and SOT recipients. Preliminary pharmaco-
inetic data suggest that systemic exposure to the
harmacologically active metabolite MPA is substan-
ially less in AlloSCT recipients [40-42]. The second
eak of MPA plasma concentration described in
ealthy volunteers and SOT recipients has not been
bserved in AlloSCT recipients, suggesting that en-
erohepatic recirculation may be impaired in patients
fter AlloSCT. The toxicity of the conditioning reg-
men leading to signiﬁcant mucosal damage is the
ost likely explanation for this effect. The destruction
f the bacterial ﬂora of the gut by broad-spectrum
ntibacterial agents, selective gut decontamination, or
oth can also lead to reduced formation of glucuron-
dase, which is essential for conversion of MPAG back
o MPA (the active metabolite). Furthermore, the
alf-life of MPA in AlloSCT recipients seems to be
igniﬁcantly shorter than reported in SOT recipients
1.5-3.6 versus 16-18 hours) [40]. This impaired de-
lucuronidation, lack of enterohepatic recirculation,
horter half-life, or a combination of these may ex-
lain in part the signiﬁcantly lower trough concentra-
ions of MPA in AlloSCT recipients observed in our
tudy and others.
The importance of monitoring MPA levels is un-
erscored by data from SOT recipients demonstrating
hat the steady-state MPA area under the curve (AUC)
nd, to a lesser extent, MPA trough concentrations
redict the risk of acute organ rejection. Maintaining
igure 6. One-year overall survival. The probability of 1-year
verall survival of 27 evaluable patients was determined by the
aplan-Meier method in all patients or those who received either
mbilical cord blood or matched family donor allogeneic stem cell
ransplants. All patients (----); average risk (— —); and poor risk
——) by International Bone Marrow Transplant Registry criteria.
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2PA AUC at the target range of 30 to 60 g.h/mL
ecreases the risk of acute rejection to 10% [43].
urrently, there is a paucity of data demonstrating a
elationship between MPA concentrations and risk of
GVHD in AlloSCT recipients. It is clear, however,
hat MPA trough concentrations and AUC are signif-
cantly decreased in AlloSCT compared with SOT
ecipients [40-42]. Because there is no established
herapeutic range for MPA trough concentrations in
he AlloSCT setting, we have adopted the range used
n the SOT setting (1-3.5 g/mL). Our preliminary
ata in 14 pediatric AlloSCT patients who underwent
teady-state MPA trough concentration monitoring
emonstrated a striking relationship between MPA
rough concentrations and the risk of aGVHD (Figure
B). Patients who did not achieve MPA trough con-
entrations 1 g/mL before day 30 had a signiﬁ-
antly higher incidence of aGVHD (100% versus
6.7% 	 15.2%; P  .02).
There was a 21% incidence of graft failure in
atients with hemoglobinopathies, hemophagocytic
r metabolic disorders, MDS, and CML. These dis-
ases are now known to be associated with a higher
egree of graft failures after both reduced-intensity
nd myeloablative transplantation [44-46]. Further-
ore, 7 of 8 patients with graft failure in our study had
eceived UCB donor stem cells, and this is also known
o be associated with a higher risk of failed engraft-
ent. We therefore believe that underlying disease
oupled with insufﬁcient ablation in the preparative
egimen, rather than the GVHD prophylactic regi-
en used, was responsible for the number of graft
ailures in our study. Our institutional protocols have
ince been revised to reﬂect the need for a more
ntensive preparative regimen.
The probability of developing grade II and
rade III to IV aGVHD with the use of FK506 and
MF in our study was 45.4% 	 9.7% and 33.8% 	
.9%, respectively. The probability of developing
rade II to IV aGVHD was higher (62.5% 	 17.1%)
n patients who received related PBSC transplants.
owever, because of the small number of patients, it
s difﬁcult to deduce whether the stem cell source
PBSC) or low MPA trough concentrations, or both,
ere contributing factors. CsA and MTX have been
idely used for aGVHD prophylaxis after AlloSCT
ith an MFD and have been associated with a 35%
ncidence of grade II to IV aGVHD and a 40% inci-
ence of cGVHD [11,47]. After transplantation of
nmodiﬁed marrow from HLA-matched unrelated
onors receiving CsA and MTX GVHD prophylaxis,
ansen et al. [48] reported a 75% incidence of
GVHD. In a randomized multicenter trial that com-
ared FK506/MTX with CsA/MTX for GVHD pro-
hylaxis after AlloSCT with matched sibling donors,
atanatharathorn et al. [22] reported a signiﬁcantly
ower incidence of grade II to IV aGVHD in patients a
56ho received FK506/MTX compared with patients in
he CsA/MTX group (31.9% versus 44.4%, respec-
ively; P  .01). The incidence of grade III to IV
GVHD was similar: 13.3% versus 17.1%. There was
o difference in the rate of doubling of creatinine
uring the study period between the 2 groups (84%
ersus 80%; P  .3), whereas in the CsA group there
as a higher incidence of hypertension that required
edication (P  .001). Hiraoka [23] also reported an
dvantage of using FK506 over CsA for preventing
GVHD after AlloSCT: the incidence of grade II to
V aGVHD was lower in the FK506 group (17.5%)
ompared with the CsA group (48%; P  .0001). A
hird randomized study, by Nash et al. [21], compared
sA/MTX with FK506/MTX for aGVHD preven-
ion after unrelated donor AlloSCT. This study dem-
nstrated a decreased incidence of aGVHD in the
K506 group compared with the CsA group (56%
ersus 74%; P .0002). There was a trend toward less
evere GVHD in the FK506 group (P  .005) with
ess glucocorticoid use compared with the CsA group
65% versus 81%; P  .019). There was also no
igniﬁcant increase in infectious complications or
ther toxicities with the use of FK506 versus CsA.
We have found that the use of FK506/MMF has
een associated with good tolerability and low over-
apping toxicities, and it may be equivalent or superior
o standard regimens in preventing aGVHD with the
ppropriate monitoring, aiming for steady-state MPA
rough concentrations of 1.0 to 3.5 g/mL. Because
MF and FK506 do not share overlapping toxicities,
t is easy to monitor for side effects that can be attrib-
ted to either drug. It has become apparent that
chievement of therapeutic levels of MMF via MPA
rough monitoring and appropriate dose adjustments
s an important component to the observed efﬁcacy
nd tolerability of this regimen. Signiﬁcantly higher
MF doses were necessary in our patients to achieve
arget MPA concentrations compared with the doses
sed in SOT recipients (900 mg/m2 every 6 hours
ersus 600 mg/m2 every 12 hours). The main limita-
ions of this observation are the small number of
atients available for analysis, the lack of information
n the target MPA trough concentrations for GVHD
revention, and the lack of consensus on the necessity
f monitoring MPA trough concentrations in either
ematopoietic or SOT recipients. In addition, total
PA trough concentrations may not be the optimal
onitoring parameter or predictor of the degree of
mmunosuppression after MMF administration. Free
PA concentration, AUC, and inosine monophos-
hate dehydrogenase measurements, alone or in com-
ination, would offer more accurate information
bout the degree of immunosuppression and the risk
f GVHD. Unfortunately, the tests are mainly used
or research purposes and are not commercially avail-
ble. The results obtained from MPA monitoring in
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Bur patient cohort suggest the possibility of a relation-
hip between the probability of developing aGVHD
nd the achievement of therapeutic MPA trough lev-
ls. These results are provocative and support the
eed for randomized controlled studies to further de-
ineate this relationship and to determine the ideal
ose schedule for MMF in pediatric and adolescent
lloSCT recipients when it is used in combination
ith FK506. These trials should be designed to com-
are the incidence of clinically signiﬁcant aGVHD
grades II-IV) with FK506/MMF compared with
K506/MTX, CsA/MTX, or both in prospective ran-
omized controlled studies.
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